Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 35,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 35,000 · Balance 35,000 F2: Not applicable. F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 23:52 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $17.52 | Not disclosed |
DisclosureSEC source: 0001963544-26-000002 · wk-form4_1767743566.xml · derivative · entry 1 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 24, 2025 01:06 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 533,617 | $18.74 | $9,999,982.58 |
DisclosureSEC source: 0001963544-25-000004 · wk-form4_1761267986.xml · nonDerivative · entry 1 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Akeso, Inc. Disclosed balance after: 32,057,147 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. F2 · ownership.nature: Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:24 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 5,438 | $9.18 Strike: $18.35 | $49,920.84 |
DisclosureSEC source: 0001599298-25-000027 · wk-form4_1736209460.xml · derivative · entry 2 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,438 Underlying: Common Stock · 5,438 shares Expires 2035-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $49,900. F3 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:24 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $18.35 | Not disclosed |
DisclosureSEC source: 0001599298-25-000027 · wk-form4_1736209460.xml · derivative · entry 1 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:19 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $2.64 | Not disclosed |
DisclosureSEC source: 0001599298-24-000008 · wk-form4_1704403182.xml · derivative · entry 2 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-02 F2 · price: Not applicable. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on January 2, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:19 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.64 | Not disclosed |
DisclosureSEC source: 0001599298-24-000008 · wk-form4_1704403182.xml · derivative · entry 1 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| March 07, 2023 Filed Feb 14, 2024 21:35 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 21,523,530 | $1.05 | $22,599,706.50 |
DisclosureSEC source: 0001999371-24-002333 · ownership.xml · nonDerivative · entry 1 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Akeso, Inc. Disclosed balance after: 21,523,530 F1 · balance_after: 21,523,530 shares of the Issuer's Common Stock were acquired on March 7, 2023 through a rights offering. F3 · ownership.nature: Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest. Read SEC document |
| January 17, 2023 Filed Feb 14, 2024 21:35 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 10,000,000 | $2.51 | $25,100,000.00 |
DisclosureSEC source: 0001999371-24-002333 · ownership.xml · nonDerivative · entry 2 Xia Yu · CIK 0001963544 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Akeso, Inc. Disclosed balance after: 10,000,000 F2 · balance_after: 10,000,000 shares of the Issuer's Common Stock were issued on January 17, 2023 in connection with the Collaboration and License Agreement with Akeso, Inc.("Akeso") pursuant to which the Issuer issued Akeso such shares. F3 · ownership.nature: Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.